MedTrace Logo

Effect of CT1812 Treatment on Brain Synaptic Density

NCT03493282 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2023-09-07

Study results available
· View outcomes & findings →

Summary

Study to Evaluate the Safety and Tolerability of Oral CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Active Treatment- CT1812 100 mg

CT1812

DRUG

Active Treatment- CT1812 300 mg

CT1812

DRUG

Placebo

Matching Placebo

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Cognition Therapeutics

    lead INDUSTRY

Principal Investigators

  • Christopher van Dyck, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-28
Primary Completion
2020-10-16
Completion
2020-10-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03493282 on ClinicalTrials.gov